Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
26 August 1987Website:
http://www.herontx.comNext earnings report:
12 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 21:58:08 GMTDividend
Analysts recommendations
Institutional Ownership
HRTX Latest News
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.
Evaluate the expected performance of Heron Therapeutics (HRTX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its Board of Directors. Mr. Kaseta has an extensive background spanning corporate finance, business strategy, and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies.
SAN DIEGO , Oct. 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 12, 2024, at 8:00 a.m. ET to report third quarter 2024 financial results and discuss recent business highlights.
SAN DIEGO , Oct. 10, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today reaffirmed the Company's ability to supply CINVANTI® (aprepitant) injectable emulsion and SUSTOL® (granisetron) extended-release injection for Chemotherapy Induced Nausea and Vomiting ("CINV") prevention and APONVIE® for Postoperative Nausea and Vomiting ("PONV") prevention given the temporary shortage of intravenous ("IV") fluids which is expected as the result of Hurricane Helene. As alternatives to products that require dilution with IV fluids, CINVANTI, SUSTOL, and APONVIE are supplied in ready-to-administer formulations that do not require additional dilution with IV fluids in what may be a time of critical shortage.
- The VAN has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF's withdrawal time - The VAN is expected to launch in Q4 2024 SAN DIEGO , Sept. 25, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the "FDA") has approved the Company's Prior Approval Supplement Application for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution VAN.
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.35 per share a year ago.
SAN DIEGO , July 30, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, August 6, 2024, at 4:30 p.m. ET to report second quarter 2024 financial results and discuss recent business highlights.
- 1(current)
- 2
What type of business is Heron Therapeutics?
Heron Therapeutics, Inc. is a commercial biotechnology company focused on improving the lives of patients by developing new methods of treating post-operative pain and cancer. Products SUSTOL and CINVANTI have been developed for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of chemotherapy, these two drugs have been approved and are already being marketed by the Company. HTX-011 for the treatment of post-operative pain is awaiting FDA approval. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
What sector is Heron Therapeutics in?
Heron Therapeutics is in the Healthcare sector
What industry is Heron Therapeutics in?
Heron Therapeutics is in the Biotechnology industry
What country is Heron Therapeutics from?
Heron Therapeutics is headquartered in United States
When did Heron Therapeutics go public?
Heron Therapeutics initial public offering (IPO) was on 26 August 1987
What is Heron Therapeutics website?
https://www.herontx.com
Is Heron Therapeutics in the S&P 500?
No, Heron Therapeutics is not included in the S&P 500 index
Is Heron Therapeutics in the NASDAQ 100?
No, Heron Therapeutics is not included in the NASDAQ 100 index
Is Heron Therapeutics in the Dow Jones?
No, Heron Therapeutics is not included in the Dow Jones index
When was Heron Therapeutics the previous earnings report?
No data
When does Heron Therapeutics earnings report?
The next expected earnings date for Heron Therapeutics is 12 March 2025